

## Scancell

### Cohort 1 SCOPE data confirms SCIB1 response rates

18 November 2024

- Much-anticipated key clinical data from Cohort 1 (SCIB1 in combination with ipilimumab and nivolumab) of the Phase II [SCOPE](#) study show meaningfully improved outcomes across all key metrics. The ORR (objective response rate) at 25 weeks was 72%, with 18/25 patients showing a clinical response. Other measures were equally positive: PFS (progression free survival) of 80% at six months (20 patients), CR (complete response) rate of 20% (five patients), DCR (stable disease or tumour regression) of 84% (18 patients). Responses were verified during scans at 19 and 25 weeks. Cohort 1 has now recruited 42/43 planned patients, with all patients due to reach week 25 during H125.
- SCOPE was configured to target an ORR of >70% ([October 2024 Update](#)), which compares favourably to the ORR of 48% seen in patients receiving CPI doublet therapy (ipilimumab and nivolumab) alone in the real-world setting. Similarly, the doublet therapy PFS is 65%, CR is 16%, and DCR is 58%. For context, these doublet therapy response rates are the highest observed in such advanced melanoma. The Cohort 1 results signal that adding SCIB1 to doublet therapy materially improves outcomes and, as the SCOPE data matures, will indicate the sustainability and durability of these responses.
- Scancell also updated on the other SCOPE cohorts. Cohort 2 (SCIB1 in combination with pembrolizumab, [Keytruda]) has recruited only 9 of the originally planned 43 patients reflecting how rarely this treatment regimen is used. Cohort 3, examining the next generation iSCIB1+ plus doublet therapy, has recruited 33 of its 43 patients with the majority of these currently being non-HLA.A2 matched patients (as the HLA.A2 patients were prioritised to Cohort 1). With Cohort 1 effectively complete (one further patient required), recruitment into Cohort 3 will be better balanced, providing a representative mix of melanoma patients. All Cohort 3 patients are expected to complete week 25 by H225.
- As a reminder, iSCIB1+ is a modified version of SCIB1 that has a broader array of melanoma epitopes so can be used across the whole patient population irrespective of HLA type. In addition, it incorporates elements from the AvidiMab platform that provide greater potency and confer extended patent protection.

Price	16.25p
Market Cap	£151.0m
Primary exchange	AIM
Sector	Healthcare
Company Code	SCLP
Corporate client	Yes

#### Company description:

Scancell is a clinical-stage immuno-oncology specialist that has four broadly applicable technology platforms. Two are therapeutic vaccines, Moditope and ImmunoBody, and two are antibody based, GlyMab and AvidiMab.

**Trinity Delta view:** Data from the SCOPE study are reassuring and pave the way for the planned randomised adaptive Phase II/III trial. Assuming continuing positive results at week 25 for both Cohorts 1 and 3, investor attention will understandably centre on the funding of this potentially pivotal study. Our forecast cash runway extends to Q325, beyond these SCIB1/iSCIB1+ milestones and Modi-1 data in H125; however, our cash assumptions do not include any potential licensing deals for the GlyMab and/or AvidiMab antibody platforms. We note that the seven-month evaluation deal with an unnamed partner could result in option exercise in Q125, which could trigger a similar upfront payment and licence deal to that struck with Genmab in October 2022. Our current risk adjusted NPV valuation for Scancell is £311m, equivalent to 33p per share.

#### Analysts

##### Lala Gregorek

lgregorek@trinitydelta.org  
+44 (0) 20 3637 5043

##### Philippa Gardner

pgardner@trinitydelta.org  
+44 (0) 20 3637 5042

**Philippa Gardner**

[pgardner@trinitydelta.org](mailto:pgardner@trinitydelta.org)

+44 (0) 20 3637 5042

**Lala Gregorek**

[lgregorek@trinitydelta.org](mailto:lgregorek@trinitydelta.org)

+44 (0) 20 3637 5043

**Franc Gregori**

[fgregori@trinitydelta.org](mailto:fgregori@trinitydelta.org)

+44 (0) 20 3637 5041

### Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at [www.fisma.org](http://www.fisma.org). TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2024 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: [www.trinitydelta.org](http://www.trinitydelta.org)